Major developments are happening in the global cannabis industry. Most recently, the European Union legalized a cannabinoid-based medication for patients aged two years and above who suffer from rare types of epilepsy; Lennox-Gastaut syndrome and Dravet syndrome. The name of that medication was Epidiolex – produced by British drug company GW Pharmaceuticals.
Long gone are the days of tie-dyed clad hippies preaching peace and love from the pulpit of the plant. Their long wavy hair and baggy clothes replaced with trendy haircuts and fitted business suits. Their old mantras of love and equality have given way to those of legislation and equity.
An Indica capable of taming the potency of Gorilla while keeping her taste intact.
Purpose of review: An increasing number of patients are turning to cannabis and cannabinoids for management of their palliative and nonpalliative cancer pain and other cancer-related symptoms. Canadians have a legal framework for access to medical cannabis, which provides a unique perspective in a setting lacking robust clinical evidence. This review seeks to delineate the role of cannabis and cannabinoids in cancer pain management and offers insight into the Canadian practice.
Introduction to the current situation in California by third-generation Emerald Triangle Farmer Casey O’Neill:
Everyone has heard of CBD and today, with all the media hype and marketing, it is hard not to have heard something about it. Even your Grandparents will have heard positive things about CBD, but what are the authorities saying?
After over a century of irresponsible treatment of our environment, our plant -humanity is in need of a quick solution. Hemp may just be one of the pieces to this giant puzzle.
Within the last decade, cannabidiol (CBD) has become one of the most popular natural alternative medicines for people around the world. With such a versatile amount of health bene¬ts, CBD seems to provide a therapeutic solution for almost anyone out there.Due to this, more and more people seek to give CBD a try.
I am talking about Sweet Pure Auto CBD® (SWS75), a 6th generation autoflowering strain included in the Sweet Seeds® therapeutic line due to its high CBD content and which has been shown a very good acceptance after its release in the market. In addition to its high cannabidiol (CBD) content, another highly valued feature is that it contains almost no THC (less than 1%), so it has no psychoactive effects.
Cannabinoid compounds include phytocannabinoids, endocannabinoids, and synthetics. The two primary phytocannabinoids are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), with CB1 receptors in the brain and peripheral tissue and CB2 receptors in the immune and hematopoietic systems.
